In English | En español
Questions About Cancer? 1-800-4-CANCER

Ovarian Epithelial Cancer Treatment (PDQ®)

  • Updated: 06/24/2014

Table 3. Regimens Used in First Relapse

Eligibility (mo) Regimen Patient Number Comparator Comments on Outcome (mo) 
Most Commonly Used
Platinum sensitive (>6)Cisplatin or carboplatin + paclitaxel802Single or nontaxane + platinumsPFS 11 vs. 9; OS 24 vs. 19 [5]
Platinum sensitive (>6)Carboplatin + gemcitabine356CarboplatinPFS 8.6 vs. 5.8; OS 18 vs. 17 [6]
Platinum sensitive (> 6)Carboplatin + pegylated liposomal doxorubicin976Carboplatin + paclitaxelPFS 11.3 vs 9.4; OS not reported [7]
Other Regimens
Platinum sensitive (>6)Carboplatin + epirubicin190CarboplatinPowered for response differences; OS 17 vs. 15 [5]
Platinum sensitive (≥12)Cisplatin + doxorubicin + cyclophosphamide97PaclitaxelPFS 15.7 vs. 9; OS 34.7 vs. 25.8 [6]
Platinum sensitive + resistantPLD + trabectedina672PLDPFS 7.3 vs. 5.8; OS 20.5 vs. 19.4b

OS = overall survival; PFS = progression-free survival; PLD = pegylated liposomal doxorubicin.
aTrabectedin has been approved for use in treating recurrent ovarian cancer in Europe and Canada.
bOS data were not mature at the time the manuscript was published.[4]


  1. Monk BJ, Herzog TJ, Kaye SB, et al.: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28 (19): 3107-14, 2010.  [PUBMED Abstract]

  2. Bolis G, Scarfone G, Giardina G, et al.: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81 (1): 3-9, 2001.  [PUBMED Abstract]

  3. Cantù MG, Buda A, Parma G, et al.: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (5): 1232-7, 2002.  [PUBMED Abstract]

  4. Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29): 4699-707, 2006.  [PUBMED Abstract]